

**Mexico Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032**

Market Report | 2023-05-01 | 78 pages | Allied Market Research

**AVAILABLE LICENSES:**

- Cloud Access License \$2119.50
- Business User License \$3213.00
- Enterprise License \$4995.00

**Report description:**

The Mexico radiopharmaceuticals market is expected to witness a favorable growth during the forecast period. With the rise in investments in R&D of radiopharmaceuticals for clinical and restorative applications, the market is expected to witness significant growth. The essential radioisotopes in the radiopharmaceuticals market in Mexico are Technetium 99m, Fluorine 18, Iodine I, Gallium 68, and also others. The significant applications of radiopharmaceuticals in Mexico include cancer, cardiology, and others. In terms of type, the major radiopharmaceuticals in the Mexican market are diagnostic and therapeutic. The major customers of radiopharmaceuticals are hospitals & clinics, medical imaging centers, and others.

The development of the Mexico radiopharmaceuticals market can be attributed to factors such as a rising prevalence of cancer worldwide, technical improvements in radiopharmaceuticals, as well as using radiopharmaceuticals for medical diagnosis of specific diseases. The rising prevalence of cancer cells in Mexico as well as the increasing demand for early diagnosis of cancer cells are anticipated to be the major factors driving the development in this market. The rising preference for nuclear medicine procedures owing to its effectiveness for imaging as well as medical diagnosis is additionally expected to drive the growth of the market. In addition, the introduction of 3D printing innovation in the production of radiopharmaceuticals is anticipated to develop opportunities for new product launches during the forecast years.

On the contrary, the rigid governing regulations as well as the high cost of radiopharmaceuticals are anticipated to act as restricting factors for the market growth. Furthermore, stringent federal government regulations regarding the supply and circulation are expected to hamper the development of the market during the forecast years.

The market environment of Mexico radiopharmaceuticals is studied by using Porter's 5 forces analysis. Threat of new participants, negotiating power of purchasers, negotiating power of distributors, threat of substitutes, and degree of competitive rivalry in the

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

market are taken into consideration. The risk of new entrants out there is mini due to stringent guidelines associated with the manufacturing and sale of radiopharmaceuticals. In addition, the presence of many well-known players in the market also restricts the entry of new players as well as creates a competitive environment in the market. The bargaining power of purchasers in the market is moderate owing to the presence of several well-known distributors. Moreover, the vendors usually offer discount rates to customers for bulk orders, which further strengthens their power in the market.

The bargaining power of distributors is low, owing to the visibility of presence distributors. In addition, customers can conveniently switch over to a different supplier owing to the presence of several providers in the market. The threat of alternatives is low, due to the benefits of radiopharmaceuticals for diagnosis and imaging. The accessibility of alternatives such as optical imaging and magnetic vibration imaging for imaging & medical diagnosis is low. The level of competitive rivalry in the market is high due to the existence of reputable players in the industry. In addition, the introduction of new modern technologies and the substantial financial investments in R&D tasks in the sector have actually increased the number of competitors in the market.

The future trends in the Mexico radiopharmaceuticals market include the introduction of new radiopharmaceuticals, R&D in the field of imaging, and the presence of new players in the market. The use of radiopharmaceuticals in targeted therapies is expected to increase in the upcoming years. In addition, the increasing awareness about the benefits of radiopharmaceuticals is anticipated to drive the growth of the market during the forecast period.

The demand need for radiopharmaceuticals from the healthcare facilities and clinical imaging facilities is expected to boost the market growth. Furthermore, the rising technical innovations in radiopharmaceuticals is expected to create possibilities for new product launches in the market. The leading players in the Mexico radiopharmaceuticals market are focusing on launching new products in the market. They are additionally investing dramatically in R&D tasks. For instance, in March 2019, the U.S.-based radioisotope business, PETnet Solutions, released a brand-new radioisotope, Technetium 99m, in Mexico. In addition, the business has actually established solution facilities in significant cities of Mexico, which offers radiopharmaceuticals to the local healthcare facilities.

The leading companies are also concentrating on expanding their manufacturing capacity. For instance, in February 2020, the Mexican radiopharmaceuticals firm, Ergomed, announced the development of its radiopharmaceuticals.

Key companies profile in the report are Sanofi, Gammaglobulin, Grupo Angel, Promecaps SA, Radiofarm SA de CV, Micro-Innova SA de CV, Nucleomex SA de CV, Plena Pharma SA de CV, Bioenex SA de CV, Farmefluar SA de CV.

The radiopharmaceuticals market share is segmented into Radioisotope, Application, Type, End User, and region. On the basis of radioisotopes, the market is classified into Technetium-99m, Fluorine-18, Iodine I, Gallium-68, and others. On the basis of application, the market is divided into cancer, cardiology, and others. On the basis of type, the market is bifurcated into diagnostic, and therapeutic. On the basis of end user, the market is fragmented into hospitals and clinics, medical imaging centers, and others. The others segment includes diagnostic centers, and research institute.?

#### Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in Mexico radiopharmaceuticals market.

Assess and rank the top factors that are expected to affect the growth of Mexico radiopharmaceuticals market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the Mexico radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

- Quarterly Update and\* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support\* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 15% Free Customization\* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response\*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

- New Product Development/ Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- SWOT Analysis

#### Key Market Segments

##### By Type

- Diagnostic
- Therapeutic

##### By End User

- Hospitals and clinics
- Medical Imaging centers
- Others

##### By Radioisotope

- Fluorine 18
- Iodine I
- Gallium 68
- Others
- Technetium 99m

##### By Application

- Cancer
- Cardiology
- Others
- Key Market Players

? Sanofi

? Gammaglobulin

? Grupo Angel

? Promecaps SA

? Radiofarm SA de CV

? Micro-Innova SA de CV

? Nucleomex SA de CV

? Plena Pharma SA de CV

? Bioenex SA de CV

? Farmefluar SA de CV

#### **Table of Contents:**

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits to the Stakeholders
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models

## CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO Perspective

## CHAPTER 3: MARKET OVERVIEW

- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Impacting Factors
  - 3.2.2. Top Investment Pockets
- 3.3. Porter's Five Forces Analysis
- 3.4. Market Dynamics
  - 3.4.1. Drivers
  - 3.4.2. Restraints
  - 3.4.3. Opportunities
- 3.5. COVID-19 Impact Analysis on the market

## CHAPTER 4: MEXICO RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE

- 4.1. Overview
  - 4.1.1. Market Size and Forecast, By Radioisotope
- 4.2. Technetium 99m
- 4.3. Fluorine 18
- 4.4. Iodine I
- 4.5. Gallium 68
- 4.6. Others

## CHAPTER 5: MEXICO RADIOPHARMACEUTICALS MARKET, BY APPLICATION

- 5.1. Overview
  - 5.1.1. Market Size and Forecast, By Application
- 5.2. Cancer
- 5.3. Cardiology
- 5.4. Others

## CHAPTER 6: MEXICO RADIOPHARMACEUTICALS MARKET, BY TYPE

- 6.1. Overview
  - 6.1.1. Market Size and Forecast, By Type
- 6.2. Diagnostic
- 6.3. Therapeutic

## CHAPTER 7: MEXICO RADIOPHARMACEUTICALS MARKET, BY END USER

- 7.1. Overview
  - 7.1.1. Market Size and Forecast, By End User
- 7.2. Hospitals and clinics
- 7.3. Medical Imaging centers
- 7.4. Others

## CHAPTER 8: COMPETITIVE LANDSCAPE

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Company 1
  - 9.1.1. Company overview
  - 9.1.2. Key Executives
  - 9.1.3. Company snapshot
  - 9.1.4. Operating business segments
  - 9.1.5. Product portfolio
  - 9.1.6. Business performance
  - 9.1.7. Key strategic moves and developments
- 9.2. Company 2
  - 9.2.1. Company overview
  - 9.2.2. Key Executives
  - 9.2.3. Company snapshot
  - 9.2.4. Operating business segments
  - 9.2.5. Product portfolio
  - 9.2.6. Business performance
  - 9.2.7. Key strategic moves and developments
- 9.3. Company 3
  - 9.3.1. Company overview
  - 9.3.2. Key Executives
  - 9.3.3. Company snapshot
  - 9.3.4. Operating business segments
  - 9.3.5. Product portfolio
  - 9.3.6. Business performance
  - 9.3.7. Key strategic moves and developments
- 9.4. Company 4
  - 9.4.1. Company overview
  - 9.4.2. Key Executives
  - 9.4.3. Company snapshot
  - 9.4.4. Operating business segments
  - 9.4.5. Product portfolio
  - 9.4.6. Business performance
  - 9.4.7. Key strategic moves and developments
- 9.5. Company 5
  - 9.5.1. Company overview
  - 9.5.2. Key Executives
  - 9.5.3. Company snapshot
  - 9.5.4. Operating business segments
  - 9.5.5. Product portfolio
  - 9.5.6. Business performance
  - 9.5.7. Key strategic moves and developments

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.6. Company 6
  - 9.6.1. Company overview
  - 9.6.2. Key Executives
  - 9.6.3. Company snapshot
  - 9.6.4. Operating business segments
  - 9.6.5. Product portfolio
  - 9.6.6. Business performance
  - 9.6.7. Key strategic moves and developments
- 9.7. Company 7
  - 9.7.1. Company overview
  - 9.7.2. Key Executives
  - 9.7.3. Company snapshot
  - 9.7.4. Operating business segments
  - 9.7.5. Product portfolio
  - 9.7.6. Business performance
  - 9.7.7. Key strategic moves and developments
- 9.8. Company 8
  - 9.8.1. Company overview
  - 9.8.2. Key Executives
  - 9.8.3. Company snapshot
  - 9.8.4. Operating business segments
  - 9.8.5. Product portfolio
  - 9.8.6. Business performance
  - 9.8.7. Key strategic moves and developments
- 9.9. Company 9
  - 9.9.1. Company overview
  - 9.9.2. Key Executives
  - 9.9.3. Company snapshot
  - 9.9.4. Operating business segments
  - 9.9.5. Product portfolio
  - 9.9.6. Business performance
  - 9.9.7. Key strategic moves and developments
- 9.10. Company 10
  - 9.10.1. Company overview
  - 9.10.2. Key Executives
  - 9.10.3. Company snapshot
  - 9.10.4. Operating business segments
  - 9.10.5. Product portfolio
  - 9.10.6. Business performance
  - 9.10.7. Key strategic moves and developments

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Mexico Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032**

Market Report | 2023-05-01 | 78 pages | Allied Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

| Select license | License               | Price     |
|----------------|-----------------------|-----------|
|                | Cloud Access License  | \$2119.50 |
|                | Business User License | \$3213.00 |
|                | Enterprise License    | \$4995.00 |
|                |                       | VAT       |
|                |                       | Total     |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|               |                      |                               |                      |
|---------------|----------------------|-------------------------------|----------------------|
| Email*        | <input type="text"/> | Phone*                        | <input type="text"/> |
| First Name*   | <input type="text"/> | Last Name*                    | <input type="text"/> |
| Job title*    | <input type="text"/> |                               |                      |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address*      | <input type="text"/> | City*                         | <input type="text"/> |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/> |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-04

Signature



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)